Colchicine Poisoning Cases in a Pediatric Intensive Care Unit: A Twenty-Year Study
- PMID: 36018729
- DOI: 10.1097/PEC.0000000000002835
Colchicine Poisoning Cases in a Pediatric Intensive Care Unit: A Twenty-Year Study
Abstract
Objectives: Colchicine intoxication is rare but potentially fatal. The toxic dose of colchicine is not well established; it has been reported that major toxicity starts after doses of 0.5 mg/kg. We aimed to evaluate the demographic, clinical aspects, treatments, and outcome of colchicine toxicity cases in the pediatric intensive care unit (PICU).
Methods: We collected the data of patients aged between 0 and 18 years, admitted to Ankara University Faculty of Medicine PICU for colchicine poisoning (n = 22), from October 1999 to January 2020, retrospectively. Data extracted from the cases included age, sex, chronic condition, time between intake of drug and admission to PICU, source of drug, amount of drug ingested, other drug intake, symptoms, clinical findings, cardiac involvement, laboratory results, time of stay in PICU, treatment, and outcome.
Results: Patients' age ranged from 7 months to 17 years. Median age was 86 months. The most common symptom at time of admission was vomiting, occurring in 13 (59%) of the patients. Two of the patients presented with change in mental status. Time between taking medication and applying to the hospital ranged from half an hour to 4 days. Medication intake of 3 of 22 patients was more than 0.5 mg/kg. One patient whose parents' best estimate of dose ingested was 0.48 mg/kg died because of the development of multiorgan failure. One patient who ingested 0.4 mg/kg of colchicine underwent plasma exchange and recovered without any complications.
Conclusions: Colchicine poisoning has a high risk of mortality, and death can be seen in doses less than a single acute dose of 0.5 mg/kg. These patients need close monitoring because there is always a risk of them to require aggressive support. Prognosis is poor in patients who have rapidly developing hemodynamic failure.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Disclosure: The authors declare no conflict of interest.
References
-
- Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep . 2002;4:252–256.
-
- Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open . 2020;3:e2013136.
-
- Marinaki S, Skalioti C, Boletis JN. Colchicine in renal diseases: present and future. Curr Pharm Des . 2018;24:675–683.
-
- Kallinich T, Haffner D, Niehues T, et al. Colcichine use in children and adolescents with familial Meditteranean fever. Pediatrics . 2007;119:474–483.
-
- Vatansever G, Karadeniz C, Kendirli T. An insidious danger in children with familial Mediterranean fever colchicine intoxication. Pediatr Emerg Care . 2015;31:652–653.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical